Latest Content
-
-
Sponsor content
Collaborative Research and Licensing Opportunity: Compounds That Treat Malaria and Prevent Malaria Transmission
The invention relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission.
-
Sponsor content
Collaborative Research and Licensing Opportunity: Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
NIH researchers have developed a tumor-targeted anthrax based toxin that selectively inactivates the blood vessels within tumors, leading to cancer cell death and tumor necrosis.
Sponsor contentCollaborative Research and Licensing Opportunity: Products for treatment and prevention of Ebola Zaire disease
Scientists at the NIAID Vaccine Research Center have developed human monoclonal neutralizing antibodies for treatment and prevention of Ebola Zaire disease.
-
Sponsor content
Collaborative Research and Licensing Opportunity: Live Attenuated Zika Virus Vaccine
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have new technology based on live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses.
Sponsor contentCollaborative Research and Licensing Opportunity: A second CD4-binding region of HIV-1 gp120 critical for viral infectivity: new methods for treatment and vaccine development
NIAID researchers have discovered a new critical component of the CD4-binding site in gp120, named CD4-BS2, which is exclusively formed in the trimeric envelope conformation.
Using BioPharma Dealmakers
All about how to get the most from the BioPharma Dealmakers website, whether you are a sponsoring Company or a Member.
Editorial content
Follow us on Twitter
BioPharma Dealmakers has just joined Twitter. Follow us for details of our latest content and partnering news stories.
Editorial content
Looking to boost your company's profile and generate leads?
Key facts about our webcasts
Diagnostics dealmaking in the past year
Medtech dealmaking and financing trends in 2016
CNS
The latest from BioPharma Dealmakers on companies, research and deals in the CNS field.
Dealmaking and differentiation in migraine’s big new market
Drug Development
The latest from BioPharma Dealmakers on companies, research and deals in the drug development field.
Unravelling the potential of nucleic-acid-based drugs
Academic/Non-profit organisation
The latest from BioPharma Dealmakers on establishments, research and deals from academic and non-profit organisations.
Opening up academic partnerships
Oncology
The latest from BioPharma Dealmakers on companies, research and deals in the oncology field.
Gastrointestinal
The latest from BioPharma Dealmakers on companies, research and deals in the gastrointestinal field.
Dealmaking for inflammatory disorders
Dermatology
The latest from BioPharma Dealmakers on companies, research and deals in the dermatology field.
